Bridging the IT Gap in Pharma, MedTech, and Biotech Commercialization

Introduction

While much of the conversation around technology in Lifesciences, Pharma, MedTech, and Biotech revolves around drug trials, regulatory compliance, and drug repurposing, there is a significant gap in discussions about the role of IT in commercialization, go-to-market strategies, and market access.

These challenges are particularly pressing because commercial success depends on seamless integration between sales execution, regulatory compliance, and market strategy that often remain disconnected in traditional IT frameworks. Companies like Vamstar can play a pivotal role in addressing these hurdles, enabling streamlined commercialization and optimized market entry.

The Overlooked IT Challenges in Commercialization

1. Scaling Market Access with Artificial Intelligence (AI) and Data Analytics

Technology leaders in life sciences are under immense pressure from multiple fronts:

• Integration with Existing Systems – New Agentic AI solutions must seamlessly integrate with legacy tech stacks, which often include decades-old Enterprise Resource Planning (ERP), Customer Relationship Management (CRM), Contract Lifecycle Management (CLM), and Pricing systems that were not built for modern AI-driven automation. This lack of compatibility creates bottlenecks, delays, and inefficiencies that hinder digital transformation. Resistance to change remains a major challenge, with organizations hesitant to alter systems that “already work.”

• Resources for AI Implementation – IT leaders often receive broad directives like “identify and deploy an AI solution that generates revenue” without clear strategic guidance or defined objectives/metrics. However, the high cost of in-house build can be a major barrier for skills, resourcing, time and costs. Without experienced industry partners, organizations often underestimate the complexity of integrating AI into commercial operations, leading to budget overruns, inefficiencies, and underwhelming results. While AI has gained traction in drug discovery and patient-facing applications, its impact on commercialization presents a faster, more scalable opportunity for efficiency gains—provided it is implemented with a structured, cost-effective approach.

• Return on Investment (ROI) – AI initiatives must deliver measurable financial and operational benefits to justify their implementation. IT leaders must balance short-term cost considerations with long-term strategic value, ensuring that AI investments drive revenue growth, enhance efficiency, and provide a competitive edge. However, many off-the-shelf AI solutions lack the necessary alignment with an organization’s strategic goals and often the Pharma, Lifesciences, MedTech, and Biotech nuances, leading to failed implementations and disappointing outcomes. Companies that successfully integrate AI into commercialization strategies can realize faster time-to-market, improved sales execution, and more accurate demand forecasting. Without clear, positive ROI and a well-defined implementation strategy, AI projects risk being labeled as expensive experiments rather than transformative solutions.

• Cybersecurity Risks – Implementing AI introduces new security challenges, including potential data breaches and compliance risks. A headline-making security incident could damage both an organization’s reputation and a technology leader’s career prospects. That’s why choosing an implementation partner with deep industry experience and a clear understanding of sector-specific needs and who can deploy AI Agents and workflows securely is critical. A knowledgeable partner can ensure AI solutions are deployed securely, align with compliance standards, and support strategic objectives, reducing the risks of system failures and regulatory penalties.

Addressing these pressures requires a structured, strategic approach that balances technological innovation with commercial viability and operational security.